Bioenergetic profile of macrophage phenotypes
Macrophages are highly adaptive cells, which respond to a plethora of environmental signals including microbial products [pathogen-associated molecular patterns (PAMPS)], activated or damaged cells, cytokines, chemokines, biologically active lipids, and modified endogenous biomolecules [danger-associated molecular patterns (DAMPs)] by acquiring distinct functional phenotypes and adjusting their metabolism to sustain their specific bioenergetic demand. While Th1 cytokines (IFNc and IL-1b) or bacterial products such as lipopolysaccharide (LPS) induce a 'classical' proinflammatory M1 phenotype, Th2 cytokines, such as IL-4 and IL-13, induce an 'alternative' anti-inflammatory and reparatory M2 phenotype [1] [2] [3] . Recent advances in the field of immunometabolism underline that the metabolic adaptation is crucial for driving macrophage phenotypic polarization and controlling bioenergetics.
Modulation of glycolysis in macrophages
Proinflammatory activation of macrophages in general, and particularly by PAMPs via Toll-like receptor (TLR) stimulation [4, 5] , induces a profound metabolic reorganization that is characterized by an increase in glucose uptake and glycolysis [5] [6] [7] [8] and a decrease in oxidative phosphorylation (OXPHOS) [9, 10] . The shift toward glycolysis occurs even in normoxic conditions and is termed aerobic glycolysis or the Warburg effect [11, 12] . The increase in glycolysis is crucial for M1 phenotypic polarization and inhibition of glycolysis was shown to prevent proinflammatory gene expression in macrophages [11, 13] . While OXPHOS is the more efficient way to generate ATP [14] , increased glycolysis could be an adaptation to compensate for the inhibition of mitochondrial respiratory ability [14] . The decrease of OXPHOS in M1 macrophages results in the accumulation of tricarboxylic acid (TCA) cycle intermediates such as citrate, succinate, fumarate, and malate, which can be used as essential precursors for anabolic processes in active cells [8, 11] . Moreover, uncoupling mitochondrial metabolism from ATP production leads to production of mitochondrial reactive oxygen species (ROS), which have been shown to contribute to macrophage bactericidal activity [15] . Regulators of glycolysis include hypoxia-inducible factor 1-a (HIF-1a), the mammalian target of rapamycin (mTOR) [16, 17] and the ubiquitous enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (uPFK2) [5] . Increased expression of uPFK2 in M1 macrophages leads to an increase in intracellular levels of fructose 2,6-bisphosphate, which by stimulating the activity of the key glycolytic enzyme 6-phosphofructo-1-kinase (PFK-1) strongly increases glycolysis [18, 19] .
Many studies use LPS to dissect the effects of inflammation on macrophage metabolism. However, recent advances show that other proinflammatory signals have substantially different effects on the metabolic state of macrophages. For instance, macrophages differentiated in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) displayed increased oxygen consumption rate and aerobic glycolysis as well as higher expression of glycolytic enzymes [20] . Moreover, the shift from OXPHOS to glycolysis is observed only in human monocytes stimulated with the TLR4 ligand LPS but not with TLR2 or TLR3 ligands, which increased both glycolysis and OXPHOS [21] . Finally, activation of the antiviral signaling response in macrophages triggered an increase in glycolysis but had no impact on OXPHOS [22] . These findings show that the shift from OXPHOS to glycolysis is not a general response of macrophages to activation by microbial or proinflammatory stimuli, but rather specific to signals that selectively induce defined metabolic programs that govern the function of macrophages.
In M2 macrophages, glucose uptake is also increased compared to quiescent cells [23] , but in contrast to M1 macrophages, glucose is mostly used to feed the TCA cycle. M2 macrophages have an increased mitochondrial respiratory capacity and present an intact TCA cycle [8] , which is essential to ensure their anti-inflammatory function [8, 24] . Some publications indicate that the metabolism of M2 macrophages mainly relies on fatty acid oxidation (FAO) to meet their bioenergetic needs and to ensure their anti-inflammatory activity [25, 26] . In that context it has been reported that CD36-dependent uptake of triglycerides (TG) followed by lipolysis via lysosomal acid lipase (LAL) feeds the TCA cycle and sustains M2 macrophage polarization upon IL-4 stimulation [26] . Thus, in mice infected with helminth parasites, inhibition of lipolysis impaired M2 activation as well as the protective immune response to this pathogen [26] . The increase in FAO after IL-4 stimulation is under the control of the nuclear receptors peroxisome proliferator-activated receptor (PPAR)-c and PPAR-d, and their coactivator PGC1b that induces mitochondrial biogenesis [25, 27, 28] . However, the dependence of M2 macrophages on FAO has been challenged by several studies. One study on human macrophages showed that despite an elevated FAO level in M2 macrophages, inhibition of FAO using etomoxir does not substantially alter IL-4-induced phenotypic polarization [29] . Similar observations have been reported in mice, where etomoxir also failed to inhibit IL-4-induced gene expression in macrophages [24] . Finally, IL-4 still induces an M2 profile in macrophages that are deficient in carnitine palmitoyltransferase 2 (CPT2), thus presenting nonfunctional FAO [30] . It appears that the controversy about the role of FAO in M2 macrophages may be attributed to unspecific effects of etomoxir when used at high doses, which may have been responsible for the impaired M2 polarization [30] . Conversely, in M1 macrophages lipolysis and FAO are strongly reduced, while oxLDL and free fatty acids (FFA) uptake as well as CD36 expression are increased [31, 32] .
In the context of atherosclerosis, it is not known how the different macrophage phenotypes that utilize glycolysis, OXPHOS and/or FAO affect plaque progression or stability. For example, an increase in glycolysis in M1-like macrophages could exaggerate inflammation, which is driven by proinflammatory compounds found in atherosclerotic lesions (Fig. 1) . On the other hand, an increase in FAO, which leads to increased FFA consumption, could explain at least partially why M2-like macrophages accumulate fewer lipids than M1-like macrophages (Fig. 2) . Further studies in this area are required to obtain new perspectives on possible novel therapeutic approaches based on macrophage metabolism.
CD-36

ABCA1 ABCG1
HDL apoAI IL-1β, IL-6, Glut1 
HIF-1a translates hypoxia into inflammation in macrophages
HIF-1a is mostly known for its role in metabolic adaptation of cells to a low oxygen level environment. However, HIF-1a is also a key factor involved in M1 macrophage phenotypic polarization. Under hypoxia, ATP production by OXPHOS is limited and cells must shift their metabolism toward glycolysis to generate sufficient amounts of ATP. HIF-1a orchestrates this shift by inducing expression of the glucose transporter Glut1 and enzymes involved in the glycolytic pathway such as hexokinase (HK), phosphofructokinase, enolase, and aldolase [48] [49] [50] . In this case, pyruvate does not fuel the TCA cycle but instead is metabolized into lactate by lactate dehydrogenase A (LDHA), which is also a HIF-1a target gene [48] . By controlling gene expression, HIF-1a supports cell survival in hypoxic conditions [51] . A similar process occurs in M1 macrophages: LPS induces HIF-1a expression in normoxic conditions, a process termed 'pseudohypoxia' [52] . HIF-1a is essential for the regulation of glycolytic capacity in M1 macrophages [16] . In the absence of HIF-1a, the intracellular ATP level as well as inflammatory cytokine production, motility, invasiveness, and phagocytosis ability are profoundly reduced [53] , leading to decreased macrophage bacteriocidal activity [53] [54] [55] . Moreover, hypoxia by itself is able to induce inflammation [56, 57] and to potentiate the inflammatory response in a HIF-1a-dependent way [58, 59] , while it reduces M2 gene expression [57] . LPS induces HIF-1a transcriptional expression through NF-jB activation [60] , whereas HIF-1a protein stabilization is mediated by metabolites such as succinate [11] or by ROS produced by NADPH oxidase [61] . Pyruvate kinase M2 (PKM2), the last enzyme of glycolysis that converts phosphoenolpyruvate (PEP) into pyruvate, plays a key role in regulating macrophage metabolism after LPS stimulation through HIF-1a [62] . Activation of macrophages by LPS promotes PKM2 dimerization which binds HIF-1a and forms a complex which induces HIF1a target genes such as IL1b and genes involved in glycolysis [62] . Thus, HIF-1a appears to be a crucial regulator of metabolic reprogramming induced in M1 macrophages. Several roles for HIF-1a in atherogenesis have been proposed, however, its contribution to the macrophage glycolytic profile and inflammation is a relatively new concept that we will discuss below.
Regulation of macrophage metabolism by mTOR and AMPK
The mammalian target of rapamycin (mTOR) is a central metabolic regulator of immunity and plays a key role in M1 macrophage polarization [63] . mTOR regulates many signaling pathways and integrates information concerning nutrient and amino acid availability, bioenergetic state, and growth factor recognition to promote anabolic processes including protein, nucleotide, and lipid synthesis [17] . Moreover, mTOR signaling plays a crucial role in lipid metabolism by promoting FA and triacylglycerol synthesis while decreasing FAO and lipolysis, leading to lipid accumulation inside cells [64] . In addition to reconfiguring cellular metabolism, mTOR signaling regulates translation and cytokine responses as well as cell migration and macrophage polarization [65] . mTOR supports the shift toward glycolysis required by M1 macrophages by increasing HIF-1a expression, leading to increased expression of glycolytic enzymes as well as inflammatory genes [66, 67] . However, the role of mTOR in macrophage polarization appears more complex since it also plays a role in M2 phenotypic polarization. In fact, several studies showed that blocking mTOR reduces M2 activation [23, 68, 69] , while others demonstrated that mTOR overexpression impaired M2 polarization and potentiated inflammation of M1 macrophages [70] .
AMP-activated protein kinase (AMPK) is a key regulator of cellular metabolism that also regulates macrophage M2 polarization. When cellular energy is low, AMPK activity is increased in response to changes in the AMP/ATP ratio [71] . Activated AMPK promotes catabolic processes including OXPHOS and FAO, whereas it inhibits anabolic reactions, such as lipid synthesis, gluconeogenesis and other nonessential ATP-consuming operations [72, 73] . AMPK up-regulates the expression of proteins involved in FAO and OXPHOS such as PGC1b [25] , and CPT1a that is essential for FA import by mitochondria [74] . AMPK directs signaling pathways in macrophages in a manner that suppresses proinflammatory responses and promotes macrophage anti-inflammatory polarization [75] . Interestingly, increased FAO by AMPK activation is essential for inhibiting lipid-induced macrophage inflammation [72] . The anti-inflammatory cytokines IL-10 and TGFb stimulate AMPK activity [75] , whereas AMPKa-deficient macrophages show defective ability to polarize into M2 macrophages [72, [75] [76] [77] . In addition, a recent article demonstrated that IL-10 counteracts the effects of proinflammatory signals by inhibiting mTOR as well as glucose uptake and glycolysis, whereas OXPHOS was promoted [78] . Moreover, AMPKa deficiency in macrophages resulted in an increased production of proinflammatory cytokines and a decrease in respiratory capacity and FAO, and a defect in efferocytosis [72, 76, 77] . Interestingly, AMPK and mTOR seem to have antagonistic effects, since activation of AMPK leads to inhibition of mTOR and decreases the proinflammatory profile of M1 macrophages [75, 79, 80] . Conversely, treatment of macrophages with LPS reduces AMPK activity [72, 81] .
Interestingly, macrophage autophagy, which is known to be protective against atherosclerosis, is also regulated by mTOR and AMPK. Autophagy is a cytoprotective response which is induced by multiple forms of cellular stress, such as starvation or oxidative stress [82] [83] [84] . Autophagy involves the sequestration of substrates including aggregated proteins, damaged organelles, or mitochondria (mitophagy) into an autophagosome for degradation, and the release of nutrients into the cytosol, which can then be used by cells as building blocks or as energy sources [82] [83] [84] , allowing enhanced cell survival in response to toxic insults [82] . Autophagy is also induced by bacterial or viral infections and participates in the regulation of the immune response against pathogens [83, 85] . Thus, autophagy is a crucial process regulating cell metabolism, resistance to toxic stress and immune response to pathogens. mTOR suppresses, while AMPK activates autophagy [86] , by regulating the serine/threonine kinases ULK1 and ULK2, which control autophagosome formation and autophagic degradation activity [82] .
Together, these findings highlight mTOR and AMPK as potentially interesting therapeutic targets to modulate macrophage metabolism in atherosclerotic plaques. Inhibition of mTOR could impair the M1-like polarization and decrease macrophage lipid content through the inhibition of lipid synthesis and the increase in FAO. On the other hand, AMPK activation could favor macrophage M2-like polarization and decrease macrophage lipid content through the stimulation of FAO and the inhibition of lipid synthesis (Fig. 3) .
Modulation of macrophage metabolism in atherosclerosis
According to the WHO, cardiovascular disease is the leading cause of mortality the western world and its prevalence is rapidly rising in developing countries. Smoking and sedentary lifestyle, as well as increasing obesity, metabolic syndrome, and diabetes are wellknown risk factors for developing atherosclerosis. Atherosclerosis was once considered a cholesterol deposition disease, but accumulating evidence shows that activation of the immune system and chronic inflammation largely contributes to atherosclerotic lesion development [87, 88] . A crucial step in atherosclerosis initiation and progression is the recruitment of monocytes into the artery wall, where they differentiate into macrophages, ingest lipoproteins, remove debris, and dead cells and eventually turn into foam cells [89] . Little is known about the metabolic adaptations of macrophages to the ever-changing microenvironment during atherosclerosis initiation and plaque progression.
The microenvironment in an atherosclerotic plaque contains proinflammatory cytokines, high levels of oxidatively modified lipids, cholesterol crystals, and a variety of DAMPs released by dying cells [90] . These inducers of inflammation likely also modify glucose utilization by macrophages [91] . Moreover, ROS are found in abundance in atherosclerotic plaques [92] , where they can damage proteins, lipids and DNA, thereby affecting cellular metabolic activity [93] . ROS can also induce mitochondrial damage leading to progressive respiratory chain dysfunction, which in turn has strong repercussions on the energetic profile of macrophages [94, 95] . Furthermore, the growth of atherosclerotic plaques is accompanied by hypoxia [96] and activation of HIF-1a [96, 97] . However, the relationship between the inflammatory status and the bioenergetic profile of plaque macrophages as well as its impact on atherosclerosis development or regression remains largely unknown.
Glucose metabolism as a master regulator of macrophage phenotypic polarization in atherosclerosis
High glucose uptake has been observed in human, mouse, and rabbit atherosclerotic plaques, such that atherosclerotic lesions can be visualized by positron emission tomography using fluorodeoxyglucose ( 18 FDG) [98] [99] [100] . In addition, oxygen consumption is increased in rabbit and monkey atherosclerotic aorta, however, despite the high glucose uptake, glucose does not feed the TCA cycle [101] . Moreover, ATP depletion and high degree of anaerobic glycolysis concomitant with high lactate production were seen in the core of advanced lesions [98] . In human lesions, high expression of GLUT-1, GLUT-3, HK1, and HK-2 in macrophage-rich regions colocalizes with HIF-1a [102] and increased GLUT-1 expression has been shown to colocalize with HIF-1a in mice [103] .
Mass spectrometry-based metabolomics analyses performed in rabbit arteries demonstrated that the levels of numerous metabolites derived from bioenergetic pathways are increased in arteries containing macrophage-rich neointima, compared with uninjured arteries or smooth muscle cell-rich neointima [104] . In particular, metabolites from glycolysis and the PPP were markedly increased as well as citrate, fumarate and succinate, similar to what is observed in activated macrophages [104] . However, it is still not well understood whether the increase in glucose metabolism is reflective of the massive macrophage infiltration into the atherosclerotic plaque and their proinflammatory activation, or if it is a result of hypoxia. Investigations of the regulation of glucose uptake in human macrophages exposed to conditions that mimic the environment in atherosclerotic lesions showed that, oxLDL, in addition to promoting inflammation, also increased glycolysis in macrophages [105, 106] . Furthermore, hypoxia may potentiate glycolytic flux and the proinflammatory phenotype in macrophages [105] . Thus, the increased glucose uptake in atheroma may be a consequence of macrophage adaptation to hypoxia, coupled with inflammatory responses to compounds found into atherosclerotic plaques.
It was shown that increased glycolysis and proinflammatory activation of macrophages upon oxLDL stimulation depended on HIF-1a, which drives glucose uptake, and the expression of HK2 and 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) [105, 106] . Moreover, inhibition of PFKFB3 and HIF-1a attenuated glycolytic flux and inflammation in atheroma in ApoE À/À mice [105] . Interestingly, oxLDL-stimulated glucose uptake and hypoxia-stimulated glycolysis both promote macrophage survival [107, 108] . Furthermore, inhibition of glycolysis reduced monocyte adherence to the endothelium, a key event in initiation of lesion formation in atherosclerosis [109] . Glycolytic regulation of macrophage metabolism is also crucial in human atherosclerosis. A recent study reported that monocytes and macrophages from patients with atherosclerosis have an increased glycolytic flux [110] . As a consequence of increased glycolysis, generation of mitochondrial ROS is increased, which promotes PKM2 dimerization and nuclear translocation, leading to IL-6 and IL-1b production [110] . Inhibition of glycolysis, scavenging superoxide, or induction of PKM2 tetramerization correct the proinflammatory phenotype of macrophages from patients with cardiovascular disease [110] . These data provide an important role for PKM2 as a link between metabolism and inflammatory regulation in macrophages in human atherosclerosis.
An investigation of the role of GLUT-1 on glucose uptake in apolipoprotein E-deficient (ApoE(À/À) mice showed that increased glucose absorption into atherosclerotic plaques of ApoE(À/À) mice is linked with an increase in metabolic activity and higher Glut1 expression of hematopoietic stem and multipotent progenitor cells [100] . Bone marrow transplantation from Glut1-deficient mice into ApoE(À/À) mice showed that Glut1 deficiency inhibited myelopoiesis, decreased glucose flux in the aortic arch, and slowed atherosclerosis progression [100] .
MicroRNA-33 (miR-33) was shown to be involved in the regulation of lipid metabolism, cholesterol efflux, HDL synthesis, and FAO [111] [112] [113] , suggesting that miR-33 controls macrophage metabolism and immune function [114] . Indeed, by targeting AMPK, miR-33 increased glycolysis, inhibited FAO and oriented macrophages toward M1 phenotypic polarization, whereas miR-33 inhibition decreased macrophage glycolysis and strongly increased OXPHOS in the presence of palmitate as well as M2 marker expression [114] . Inhibition of miR-33 in Ldlr À/À mice treated with an anti-miR-33 inhibits the progression of atherosclerosis [114] . Atherosclerotic plaques of mice treated with anti-miR-33 showed lower neutral lipid content, a reduction in necrotic size area compared to control plaques and a trend toward increased plaque collagen, while macrophage content was not changed [114] . Interestingly, analysis of macrophage phenotype revealed an increased expression of M2 markers, whereas the expression of proinflammatory genes was decreased [114] .
The intriguing link between hyperglycemia and atherosclerosis
With regard to the macrophage glycolytic profile in atherosclerosis, the role of glucose availability in the environment could be crucial for the development of atherosclerosis. Interestingly, diabetes strongly predisposes to atherosclerosis [115] . However, mechanisms that promote and accelerate atherosclerosis in diabetes are poorly understood. Hyperglycemia associated with type 1 or type 2 diabetes mellitus is an independent risk factor for atherosclerosis and cardiovascular events [116] [117] [118] [119] . Increased inflammatory activation of macrophages is a hallmark of diabetes [120] . Hyperglycemia and increased glucose availability would favor increased glucose flux and glycolysis in macrophages, resulting in macrophage inflammatory activation. Interestingly, monocytes or macrophages exposed to high glucose concentration present an M1 profile [121, 122] . Moreover, Glut1 overexpression by increasing glycolysis drives a proinflammatory phenotype similar to M1 macrophages [123] . Furthermore, hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis [124] , whereas lowering hyperglycemia has been shown to reduce monocytosis and monocyte migration into atherosclerotic plaques, and to promote plaque regression [120] . High glucose levels promote leukocyte-endothelial cell interactions and migration which are essential for atherosclerosis initiation [125] . Thus, it has been suggested that glucose lowering could be an efficient strategy to decrease the atherosclerosis risk in diabetic patients. However, in type 1 diabetic patients control of glycemia reduced major cardiovascular events [119] , several studies conducted in type 2 diabetic patients showed that glycemic control did not result in a reduction of cardiovascular events [126] . This could be due to the fact that type 2 diabetes frequently is associated with other cardiovascular risk factors such as obesity, hypertension, and dyslipidemia, which could mask the beneficial effects of glucose lowering [126, 127] . In addition, forcing myeloid cells to increase glucose uptake and glycolysis through overexpression of Glut1 neither resulted in increased atherosclerosis nor did it mimic the effect of diabetes mellitus on myeloid cells in Ldlr À/À mice [128] . Together, these findings imply that increased glucose availability may not be sufficient to drive macrophage-mediated inflammation, however, elevated glucose may contribute to potentiate inflammation, particularly in high glucose-demanding cells such as activated M1 macrophages. Further studies are needed to fully understand the role of hyperglycemia in macrophage activation as it relates to the increased incidence of atherosclerosis in diabetic patients.
Defective oxidative phosphorylation as driver for atherosclerosis?
Excessive mitochondrial oxidative stress, accumulation of damaged mitochondrial DNA, and progressive respiratory chain dysfunction are associated with atherosclerosis [94] . In atherosclerosis mitochondrial oxidative damage is induced in macrophages [129] by molecules that accumulate in atherosclerotic lesions, such as Lp(a) [130] , oxPAPC, or oxLDL [129, 130] . Mitochondrial dysfunction may impede the metabolic shift toward OXPHOS, which occurs in M2 macrophages, leading to a decrease in M2 macrophages in atherosclerotic plaques. Interestingly, inhibition of mitochondrial oxidative stress suppressed macrophage inflammatory cytokine and chemokine expression [129] . Using a mouse genetic engineering strategy, in which the oxidative stress suppressor catalase is ectopically expressed in macrophage mitochondria, resulted in suppressed macrophage accumulation, inflammation, and reduced atherosclerotic lesions in Ldlr À/À mice [129] . M1 macrophages that mainly rely on glycolysis accumulate lipid droplets, whereas M2 macrophages do not accumulate lipid droplets to the same extent, but rather consume lipids through FAO, a process which requires oxygen [26] . The low availability of oxygen in hypoxic conditions inhibits OXPHOS [131] , thus, it is tempting to speculate that the lack of oxygen availability in atherosclerotic lesions could contribute to lipid accumulation in lesion macrophages through the inhibition of FAO. Interestingly, hypoxia causes a reduction in FAO and increases TG synthesis, which leads to accumulation of TG-containing cytosolic lipid droplets in macrophages [132] . Furthermore, hypoxia induces cholesterol accumulation through an increase in cholesterol synthesis and a decrease in cholesterol efflux [96, 133] . TG and cholesterol accumulation due to hypoxia appear to be partially dependent of HIF1a, since its down-regulation reverses the effect of hypoxia, whereas HIF-1a stabilization conditions mimics the effect of hypoxia [96] . Interestingly, lipid synthesis and accumulation in macrophages under hypoxic conditions is dependent on increased glucose uptake [134] . In atherosclerotic plaques, HIF-1a colocalized with macrophages and with lipid droplets, whereas HIF-1a deficiency in myeloid cells reduced atherosclerosis in aortas of Ldlr À/À mice by more than 70% [103] . Reversal of hypoxia in Ldlr À/À mice by breathing the hyperoxic gas carbogen (composed of 95% O 2 and 5% CO 2 ) efficiently reduced plaque hypoxia and slightly increased the proportion of M2 macrophages, which decreased IL-6 production as well as necrotic core size by increasing efferocytosis of apoptotic cells [57] . This result suggests that restoring normoxia impacts macrophage phenotypic polarization. Therefore, targeting macrophage bioenergetics could be an efficient therapeutic strategy to combat atherosclerosis [57] .
Metabolic changes in macrophages during efferocytosis
Efferocytosis or phagocytosis of apoptotic cells by specialized phagocytes such as macrophages [135] or by nonspecialized phagocytes such as smooth muscle cells (SMC) is an important process to limit plaque progression and inflammation [136, 137] . Efferocytosis removes apoptotic cells in the plaque to limit the release of DAMPs by secondary necrosis of dying cells [136, 137] . Moreover, efferocytosis triggers an antiinflammatory response in macrophages by decreasing proinflammatory and increasing anti-inflammatory cytokine production [138] [139] [140] [141] . The engulfment of apoptotic cells leads to a drastic increase in intracellular lipid, protein, nucleotide, and carbohydrate content and thus represents a metabolic challenge for the macrophage, which has to handle the vast metabolite excess. But how macrophages reorganize their metabolism after efferocytosis is still not well understood. It has been observed that during the engulfment of apoptotic cells the mitochondrial membrane potential of phagocytes increases while the ATP levels stay constant, suggesting that ATP production is uncoupled from OXPHOS. The uncoupling protein 2 (UCP2), whose expression is increased during the efferocytosis process, was shown to trigger mitochondrial uncoupling in macrophages [142] . Deficiency of UCP2 leads to a further increase in the mitochondrial membrane potential and an impairment of efferocytosis. As a result of excess lipids, FAO is also increased during efferocytosis [142] . On the other hand, an excess of glucose impairs macrophage efferocytosis capacity [142, 143] . Interestingly, M2 macrophages were shown to have a greater efferocytosis capacity than M1 macrophages, suggesting that differences in metabolism could determine efferocytosis ability in macrophages [144, 145] . Finally, the atherosclerotic microenvironment influences macrophage efferocytosis ability: inflammation [144] , oxidative stress [146] as well as oxidized LDL [147] and hypoxia [57] , all known to modify macrophage metabolism, were also shown to inhibit efferocytosis in atherosclerosis [136, 148] .
A role for the pentose phosphate pathway in atherosclerosis
The pentose phosphate pathway (PPP) has a dual role in controlling the redox state of cells: through the production of NADPH, the PPP is essential to protect cells against oxidation by fueling numerous antioxidative systems. Conversely, NADPH is also used by NADPH oxidase to produce ROS. During M1 phenotypic polarization of macrophages, increased glycolysis is accompanied by an increase in PPP activity, which is essential to sustain macrophage inflammation [10] . The PPP is crucial for lipid, cholesterol, and nucleotide synthesis, which are particularly important for proliferating cells [149] .
Increased metabolites from the PPP were found in rabbit atherosclerotic arteries [104] . The few studies that focus on the role of the PPP in atherosclerosis point out a detrimental role for the PPP in lesion formation. Indeed, inhibition of the PPP by dehydroepiandrosterone reduced atherosclerotic lesion formation [150, 151] . Furthermore, G6PD deficiency decreased ROS and NO production as well as VCAM expression in aortic lesions and reduced atherosclerotic lesions in apoE À/À mice [152] . Interestingly, G6PD
deficiency is also associated with lower plasma levels of cholesterol [152] . Despite the essential role of the PPP in controlling inflammation, lipid synthesis and oxidative stress, studies concerning the PPP in macrophages in the context of atherosclerosis are limited. However, it is reasonable to speculate that the PPP plays a crucial role in lesion macrophages by participating in lipid accumulation, inflammation, and macrophage proliferation [153] as well as in adaptation to toxic stress signals such as heme in areas of intraplaque haemorrhage [154] .
mTOR and AMPK as therapeutic targets in atherosclerosis?
mTOR has been identified as an important factor in the development of atherosclerosis. Genetic or pharmacological inhibition of mTOR markedly decreased macrophage infiltration, lesion size, and inflammation [155] [156] [157] [158] [159] . In addition, mTOR inhibition exerts some of its beneficial effects on atherosclerotic plaques by promoting macrophage autophagy [160] . Macrophage autophagy plays a protective role in atherosclerosis since its inhibition worsens atherosclerosis development by increasing macrophages cell death, inflammation, and oxidative stress while decreasing macrophage efferocytosis [161, 162] . Autophagy has been implicated in the degradation of intracellular lipid droplets by a process termed lipophagy as well as in cholesterol homeostasis [163] [164] [165] . Interestingly, defects in macrophage autophagy are also associated with the progression of atherosclerosis through dysregulation of cholesterol metabolism [161, 164] . Due to its inhibitory effect on autophagy, mTOR activation enhances macrophage lipid accumulation, and foam cell formation. In contrast, blocking mTOR suppressed foam cell formation [166] , revealing mTOR inhibition as a promising strategy to treat atherosclerosis. The AMPK activation was shown to promote autophagy in smooth muscle cells thereby preventing foam cell formation [167] . Studies in macrophages show that AMPK activates the nuclear hormone receptor liver X receptor a (LXRa) which in turn increases ATP-binding cassette transporters 1 (ABCA1) and ATP-binding cassette subfamily G member 1 (ABCG1) expression, resulting in an increase in cholesterol efflux and prevention of foam cell formation [168] [169] [170] . AMPK was reported to have several athero-protective functions [171] , either due to its role as a suppressor of endoplasmic reticulum stress in the endothelium [172] or by reducing oxidative stress and vascular inflammation through the induction of UCP2 expression [173] . In macrophages, increased UCP2 expression is associated with a higher efferocytosis capacity [142, 174] and since AMPK plays a key role in the clearance of apoptotic cells [72, 76, 77, 175] , it would be interesting to further explore a role for a possible AMPK-UCP2 axis in regulating macrophage efferocytosis capacity in the context of atherosclerosis.
Conclusion and outlook
Chronic inflammation is the hallmark of atherosclerosis. Macrophages, presumably of the M1 phenotype, are important sources of proinflammatory mediators that elicit the recruitment and the activation of additional macrophages and other immune cells thus continuously promoting inflammation and plaque progression. On the other hand, M2 macrophages are sources of anti-inflammatory mediators and may limit inflammation as well as atherosclerosis progression. Thus, modulation of macrophage polarization toward the M2 phenotype or decreasing the ability of macrophages to adopt an M1 phenotype could be effective therapeutic approaches to improve atherosclerosis. Recent advances in the field of immunometabolism highlight the potential of modulating the metabolism of macrophages to affect phenotypic polarization and functions. Understanding the mechanisms that regulate the metabolic adaptation of M1 and M2 macrophages represents a great opportunity to identify new therapeutic targets in chronic inflammatory diseases such as atherosclerosis. By modulating the macrophage metabolism it would be possible to influence the macrophage inflammatory state as well as to reinforce or inhibit useful or deleterious macrophage functions, including autophagy, cell survival, efferocytosis, or cholesterol efflux.
Here, we summarized and discussed the most recent findings that point to a pivotal role for macrophage metabolism in the development of atherosclerosis. Increased glycolysis, hypoxia, or defective respiratory capacity, as well as mTOR activation, are associated with an M1 macrophage phenotype, characterized by inflammation and lipid accumulation (Fig. 1) . On the other hand, high OXPHOS and FAO are associated with M2 macrophages, decreased inflammation, and lipid content, presumably limiting atherosclerosis progression (Fig. 2) . While many studies are still necessary to clarify the role of the macrophage metabolic profile in the initiation and progression of atherosclerosis, AMPK already appeared as a key regulator and a possible therapeutic target. Increasing AMPK activation could drive macrophage polarization to an M2 phenotype and stimulate autophagy and efferocytosis. Moreover, by its ability to induce cholesterol efflux as well as FAO, AMPK activation could contribute to decrease foam cell lipid content, opening the way to atherosclerotic plaque regression (Fig. 3) .
The majority of studies on macrophage phenotypic polarization have been performed in murine models, and it is important to note that there are significant species differences when it comes to the relative importance of phenotypic markers. Moreover, most of the studies on macrophage metabolism focus on the initial bipolar view of M1 and M2 phenotypically polarized macrophages. However, new macrophage phenotypes with unique functional capabilities that may play crucial roles in atherogenesis have been recently identified. These macrophages have properties and characteristics which differ from the M1 and M2 macrophages, challenging the M1/M2 paradigm [176] . Among these new macrophage subtypes are the M4 macrophages that develop in response to stimulation with C-X-C motif chemokine 4 (CXCL4), present a defective phagocytic capacity and could contribute to the development of atherosclerosis [177] . Mox macrophages emerge in response to oxidized phospholipids and are characterized by nuclear factor, erythroidderived 2, like 2 (Nrf2)-dependent gene expression [178] . Mox macrophages represent 30% of all macrophages in advanced murine atherosclerotic lesions and present decreased phagocytotic and migratory capacity [178] . Finally, Mhem or M(Hb) macrophages develop in the presence of heme or hemoglobin, and are associated with microvessel hemorrhage in atherosclerotic plaques [179] [180] [181] [182] . Mhem or M(Hb) macrophages, have anti-inflammatory properties and are resistant to foam cell formation and thus are believed to be atheroprotective. Interestingly, heme activates AMPK, which in turn increases FAO and cholesterol efflux [180] . Interestingly, in atherosclerosis, M2-like macrophages have been recently associated not only with hemorrhage [182] but also with calcified areas in atherosclerosis [183] . Despite the growing interest in these new macrophage phenotypes, very little is known about their bioenergetics and metabolic profile. Thus, it could appear that a specific macrophage phenotype is associated with a different metabolic adaptation. Further investigation is required in order to elucidate the mechanisms that govern the metabolic adaptation of macrophages to extracellular microenvironmental signals, and to develop new therapeutic strategies to combat atherosclerosis. 
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